Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Neutral 50.2%

Neg 0% Neu 50.2% Pos 0%

Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.